0000000000256139

AUTHOR

Korbinian Berschneider

showing 4 related works from this author

Disease Progression in COPD Patients Classified as Gold D According to Gold 2011 or Gold 2017 in the Real-Life Daccord Study

2019

medicine.medical_specialtybusiness.industryCopd patientsInternal medicineDisease progressionMedicinebusinessC102. COPD: RISK PREDICTION AND PROGNOSIS
researchProduct

Patients in clinical trials on COPD triple therapy compared to real world populations

2019

Clinical trialCOPDmedicine.medical_specialtybusiness.industryInternal medicinemedicinemedicine.diseasebusiness61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
researchProduct

Characterization of COPD Patients Experiencing Clinically Relevant Improvement Vs Worsening in Health Status 2 Years After a Change of Maintenance Tr…

2019

medicine.medical_specialtyCopd patientsbusiness.industryMedicinebusinessIntensive care medicineD23. COPD: DIAGNOSIS AND EPIDEMIOLOGY
researchProduct

The frequent exacerbator in real-life: an analysis of the DACCORD study

2019

Introduction: Exacerbation prevention is a major treatment goal in COPD. Hence, exacerbations are a decisive diagnostic and prognostic factor when it comes to therapy. The non-interventional prospective DACCORD study was following COPD patients for 2 years. Here, we compare patients with frequent exacerbations, non-frequent exacerbations and no exacerbations in the 6 months prior to study entry. Methods: DACCORD recruited COPD patients following a change or initiation of COPD maintenance. Data collected at baseline and every 3 months include exacerbations and COPD medication use. COPD Assessment Test (CAT) data were collected anually. Results: Out of 6527 patients, 7.1% were frequent exacer…

COPDmedicine.medical_specialtyPrognostic factorExacerbationbiologybusiness.industryCopd patientsTreatment goalsLamamedicine.diseasebiology.organism_classificationRegimenInternal medicinemedicineIn real lifebusinessAirway pharmacology and treatment
researchProduct